510(k) · Radiology

SpotLight/SpotLight Duo with Low Dose Lung Cancer Screening Option

by Arineta Ltd.

SpotLight/SpotLight Duo with Low Dose Lung Cancer Screening Option is an AI-enabled medical device from Arineta Ltd. that the U.S. FDA cleared through 510(k) K241200 on January 13, 2025. Its lead review panel is Radiology and its primary product code is JAK (System, X-Ray, Tomography, Computed).

See also FDA-cleared AI radiology devices in 2025, all FDA AI clearances in 2025, top radiology AI devices.

Key facts

Submission numberK241200
Pathway510(k)
Date of final decision
Company (FDA list)Arineta Ltd.
Lead review panelRadiology
Primary product codeJAK — System, X-Ray, Tomography, Computed
Applicant (openFDA)Arineta , Ltd.
Applicant locationCaesarea, IL
Device classClass 2
Regulation number21 CFR 892.1750
Decision codeSESE
Submission typeTraditional

Source: FDA AI-Enabled Medical Devices list and openFDA.

What this means

A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. SpotLight/SpotLight Duo with Low Dose Lung Cancer Screening Option went through this pathway (K241200).

openFDA lists it as a Class 2 device under 21 CFR 892.1750. Class II devices are moderate risk and are subject to general and special controls.

Product code JAK covers 103 devices on the FDA AI list. By decision date, this device is #80 of 103 under that code. Arineta Ltd. has 3 AI-enabled devices on the list, and the Radiology panel accounts for 1,230 in total.

Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.

Similar devices (product code JAK)

More from Arineta Ltd.